<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">76391</article-id><article-id pub-id-type="doi">10.7554/eLife.76391</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Elevated brain-derived cell-free DNA among patients with first psychotic episode - a proof-of-concept study</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-265947"><name><surname>Lubotzky</surname><given-names>Asael</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0460-0084</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-266936"><name><surname>Pelov</surname><given-names>Ilana</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-266937"><name><surname>Teplitz</surname><given-names>Ronen</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-266935"><name><surname>Neiman</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-266938"><name><surname>Smadja</surname><given-names>Adama</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-266944"><name><surname>Zemmour</surname><given-names>Hai</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-242952"><name><surname>Piyanzin</surname><given-names>Sheina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-242954"><name><surname>Ochana</surname><given-names>Bracha Lea</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-266940"><name><surname>Spalding</surname><given-names>Kirsty L</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-242966"><name><surname>Glaser</surname><given-names>Benjamin</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4711-5000</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-242967"><name><surname>Shemer</surname><given-names>Ruth</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" corresp="yes" id="author-19651"><name><surname>Dor</surname><given-names>Yuval</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2456-2289</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes" id="author-266941"><name><surname>Kohn</surname><given-names>Yoav</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Developmental Biology and Cancer Research</institution>, <institution>The Hebrew University-Hadassah Medical School</institution>, <addr-line><named-content content-type="city">Jerusalem</named-content></addr-line>, <country>Israel</country></aff><aff id="aff2"><institution content-type="dept">Eitanim Psychiatric Hospital</institution>, <institution>Jerusalem Mental Health Center</institution>, <addr-line><named-content content-type="city">Jerusalem</named-content></addr-line>, <country>Israel</country></aff><aff id="aff3"><institution content-type="dept">Department of Cell and Molecular Biology</institution>, <institution>Karolinska Institutet Innovations</institution>, <addr-line><named-content content-type="city">Stockholm</named-content></addr-line>, <country>Sweden</country></aff><aff id="aff4"><institution content-type="dept">6Department of Endocrinology and Metabolism Service</institution>, <institution>Hebrew University of Jerusalem</institution>, <addr-line><named-content content-type="city">Jerusalem</named-content></addr-line>, <country>Israel</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-269533"><name><surname>Lam</surname><given-names>Jacky</given-names></name><role>Reviewing editor</role><aff><institution>Chinese University of Hong Kong</institution>, <country>Hong Kong</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>shemer.ru@mail.huji.ac.il</email> (RS);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>yuvald@ekmd.huji.ac.il</email> (YD);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>yoavk@ekmd.huji.ac.il</email> (YK);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>14</day><month>06</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e76391</elocation-id><history><date date-type="received"><day>15</day><month>12</month><year>2021</year></date><date date-type="accepted"><day>06</day><month>06</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Lubotzky et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Lubotzky et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-76391-v1.pdf"/><abstract><p>Schizophrenia is a common, severe and debilitating psychiatric disorder. Despite extensive research there is as yet no biological marker that can aid in its diagnosis and course prediction. This precludes early detection and intervention. Imaging studies suggest brain volume loss around the onset and over the first few years of schizophrenia, and apoptosis has been proposed as the underlying mechanism. Cell-free DNA fragments (cfDNA) are released into the bloodstream following cell death. Tissue-specific methylation patterns allow the identification of the tissue origins of cfDNA. We developed a cocktail of brain specific DNA methylation markers, and used it to assess the presence of brain-derived cfDNA in the plasma of patients with a first psychotic episode. We detected significantly elevated neuron- (p=0.0013), astrocyte- (p=0.0016), oligodendrocyte- (p=0.0129) and whole brain-derived (p=0.0012) cfDNA in the plasma of patients during their first psychotic episode (n=29), compared with healthy controls (n=31). Increased cfDNA levels were not correlated with psychotropic medications use. Area Under the Curve (AUC) was 0.77, with 65% sensitivity at 90% specificity in patients with a psychotic episode. Potential interpretations of these findings include increased brain cell death, disruption of the blood-brain barrier or a defect in clearance of material from dying brain cells. Brain-specific cfDNA methylation markers can potentially assist early detection and monitoring of schizophrenia and thus allow early intervention and adequate therapy.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Award of the National Institute of Psychobiology in Israel and the Israeli Society of Biological Psychiatry</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lubotzky</surname><given-names>Asael</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003977</institution-id><institution>Israel Science Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Dor</surname><given-names>Yuval</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Grail</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Dor</surname><given-names>Yuval</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Award of the National Institute of Psychobiology in Israel and the Israeli Society of Biological Psychiatry</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pelov</surname><given-names>Ilana</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Daniel Neiman, has filed patents on cfDNA analysis technology (year 2019, application number 62/828,587).</p></fn><fn fn-type="conflict" id="conf3"><p>Hai Zemmour, has filed patents on cfDNA analysis technology (year 2019, application number 62/828,587).</p></fn><fn fn-type="conflict" id="conf4"><p>Benjamin Glaser, has filed patents on cfDNA analysis technology (year 2019, application number 62/828,587).</p></fn><fn fn-type="conflict" id="conf5"><p>Ruth Shemer, has filed patents on cfDNA analysis technology (year 2019, application number 62/828,587).</p></fn><fn fn-type="conflict" id="conf6"><p>Yuval Dor, has filed patents on cfDNA analysis technology (year 2019, application number 62/828,587).</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: This study was conducted according to protocols approved by the Jerusalem Mental Health Center Institutional Review Board, in accordance with the Declaration of Helsinki (HMO-14-0198).We recruited men and women over 18 years of age, who have developed psychotic symptoms for the first time in their life within the last year and were admitted to the acute psychiatric units of the Jerusalem Mental Health Center in Israel.Blood samples were obtained after the initial stabilization and partial remission of the psychotic symptoms which enabled the patients to give written informed consent for participation in the study. The time achieving stability was different for each individual patient, but the majority stabilized within 4 weeks (79%). The patients were asked to complete a short questionnaire regarding demographic details, current physical condition, the onset of present symptoms and drug use. The recruitment was done following the approval of the study's protocol by the Jerusalem Mental Health Center Institutional Review Board. Patients with acute medical conditions in the week prior to the blood sampling were excluded from the study.31 adult volunteers participated in the study as unpaid healthy controls.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All relevant data including information on the markers used (coordinates and primer sequences), detailed information on patients and donors and the raw data on values of each methylation marker in each sample is provided in Source data 1. This data was used to generate the graphs shown in the paper.Detailed PCR conditions are detailed in the Materials and methods section and were published in a recent paper. Code is uploaded to GitHub as described in the paper (https://github.com/Joshmoss11/btseq).</p></sec><supplementary-material><ext-link xlink:href="elife-76391-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>